MPM Capital

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Orna Therapeutics is a biotechnology company focused on designing and delivering fully engineered circular RNA (oRNA) therapeutics. Its platform combines engineered circular RNA constructs that drive protein expression with delivery solutions, notably lipid nanoparticles, to enable safe and effective in vivo therapies. The approach expands therapeutic possibilities across diseases such as oncology, autoimmune diseases, and infectious diseases. Established in 2019 and based in Cambridge, Massachusetts, Orna Therapeutics pursues therapies built on oRNA constructs designed to express therapeutic proteins in a controlled manner.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Orna Therapeutics is a biotechnology company focused on designing and delivering fully engineered circular RNA (oRNA) therapeutics. Its platform combines engineered circular RNA constructs that drive protein expression with delivery solutions, notably lipid nanoparticles, to enable safe and effective in vivo therapies. The approach expands therapeutic possibilities across diseases such as oncology, autoimmune diseases, and infectious diseases. Established in 2019 and based in Cambridge, Massachusetts, Orna Therapeutics pursues therapies built on oRNA constructs designed to express therapeutic proteins in a controlled manner.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. It aims to deliver disease-modifying therapeutics to skeletal, cardiac, and smooth muscle, addressing conditions such as muscular dystrophies and other muscle disorders. The company uses the FORCE platform to create targeted therapeutics with payloads designed to address the disease gene, connected via a linker to an antigen-binding fragment, enabling delivery to muscle tissue and the central nervous system. Its pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. Headquartered in Waltham, Massachusetts.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Orna Therapeutics is a biotechnology company focused on designing and delivering fully engineered circular RNA (oRNA) therapeutics. Its platform combines engineered circular RNA constructs that drive protein expression with delivery solutions, notably lipid nanoparticles, to enable safe and effective in vivo therapies. The approach expands therapeutic possibilities across diseases such as oncology, autoimmune diseases, and infectious diseases. Established in 2019 and based in Cambridge, Massachusetts, Orna Therapeutics pursues therapies built on oRNA constructs designed to express therapeutic proteins in a controlled manner.

Triplet Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for triplet repeat expansion disorders, such as Huntington's disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these conditions at their source by utilizing a unique approach that involves a single oligonucleotide targeting the DNA Damage Response pathway. This strategy is designed to provide effective treatments for multiple repeat expansion disorders, enabling healthcare professionals to offer advanced biotherapeutic options to their patients. Through its research and development efforts, Triplet Therapeutics is committed to transforming the landscape of treatment for these challenging genetic disorders.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. It aims to deliver disease-modifying therapeutics to skeletal, cardiac, and smooth muscle, addressing conditions such as muscular dystrophies and other muscle disorders. The company uses the FORCE platform to create targeted therapeutics with payloads designed to address the disease gene, connected via a linker to an antigen-binding fragment, enabling delivery to muscle tissue and the central nervous system. Its pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. Headquartered in Waltham, Massachusetts.

TriNetX, Inc. operates a global health research network that facilitates clinical research and enhances the discovery of new therapies. The company provides a suite of tools, including TriNetX Live for analyzing patient populations, TriNetX Research for accessing longitudinal clinical data, and TriNetX Download for obtaining real-world clinical data through a unified platform. Additionally, TriNetX offers Attract Trials to streamline collaboration, Natural Language Processing to extract clinical information from physician notes, and specialized oncology solutions to link researchers with clinical and genomic data. Serving healthcare organizations, biopharmaceutical companies, and contract research organizations, TriNetX aims to optimize clinical trial design and recruitment, improving the speed and efficiency of bringing new therapies to market. Established in 2013, the company is headquartered in Cambridge, Massachusetts, with additional offices in Sydney, London, and Sao Paulo.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

Potenza Therapeutics, Inc. is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, established in 2014. The company is dedicated to developing a portfolio of oncology programs that harness the body's immune system to identify and eliminate tumors. Potenza's innovative approach focuses on understanding the mechanisms that allow cancer cells to evade immune detection and destruction. By leveraging these biological insights, the company aims to create effective and reliable therapeutic solutions that enhance patient health and improve cancer treatment outcomes.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions designed to streamline clinical research for sites, sponsors, contract research organizations (CROs), and patients. Founded in 2006 and headquartered in Horsham, Pennsylvania, with additional offices in Winston-Salem and Cary, North Carolina, Philadelphia, Pennsylvania, and Cambridge, Massachusetts, the company offers a suite of innovative tools including SureSource, an electronic source platform that captures data and documents at the site level, and Lunexis ePRO+, which facilitates patient participation in studies. Additionally, Clinical Ink provides CentrosHealth, a patient engagement platform that includes configurable apps to enhance patient involvement and compliance throughout clinical trials. The company aims to improve clinical trial workflows by integrating electronic data capture and reducing manual processes, ensuring that clients have access to high-quality, validated data.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

Mitobridge, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing small molecule therapeutics that enhance mitochondrial function. The company aims to address diseases associated with mitochondrial dysfunction, including genetic, metabolic, and neurodegenerative disorders, as well as age-related conditions. One of its key pipeline products is MA-0211, an orally bioavailable PPARd modulator designed to reverse mitochondrial deficits in patients with Duchenne muscular dystrophy. Founded in 2013 and formerly known as Mitokyne, Inc., Mitobridge operates with a strategy that emphasizes establishing proof of concept in rare diseases before expanding into more prevalent conditions. The company has assembled a team of experts in mitochondrial biology and related fields, with a commitment to advancing innovative therapeutics into clinical settings. As of early 2018, Mitobridge operates as a subsidiary of Astellas Pharma Inc.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

CoStim Pharmaceuticals Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative antibody agents for cancer treatment. Established in 2011, the company specializes in cancer immunotherapy and is dedicated to creating antibody drugs that target immunological checkpoint control, aiming to enhance the body’s immune response against cancer cells.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

CoStim Pharmaceuticals Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative antibody agents for cancer treatment. Established in 2011, the company specializes in cancer immunotherapy and is dedicated to creating antibody drugs that target immunological checkpoint control, aiming to enhance the body’s immune response against cancer cells.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Mitobridge, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing small molecule therapeutics that enhance mitochondrial function. The company aims to address diseases associated with mitochondrial dysfunction, including genetic, metabolic, and neurodegenerative disorders, as well as age-related conditions. One of its key pipeline products is MA-0211, an orally bioavailable PPARd modulator designed to reverse mitochondrial deficits in patients with Duchenne muscular dystrophy. Founded in 2013 and formerly known as Mitokyne, Inc., Mitobridge operates with a strategy that emphasizes establishing proof of concept in rare diseases before expanding into more prevalent conditions. The company has assembled a team of experts in mitochondrial biology and related fields, with a commitment to advancing innovative therapeutics into clinical settings. As of early 2018, Mitobridge operates as a subsidiary of Astellas Pharma Inc.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Innovative Spinal Technologies is a spine technology company based in Mansfield, Massachusetts, established in 2002. The company specializes in the development of motion preservation and minimally invasive treatments for spinal disorders. Its product portfolio includes the AXIENT Dynamic Fixation system, a pedicle screw-based motion system, and the PARAMOUNT Lumbar Fusion System, designed for lumbar fusion procedures in various surgical approaches, including minimally invasive and open techniques. Additionally, the PARAMOUNT MIS Pedicle Screw System caters to both single and multi-level procedures, while the PARAMOUNT Open Pedicle Screw System is tailored for minimally invasive lumbar fusion. The PARAMOUNT VBR is specifically engineered for a minimally invasive transforaminal approach, reflecting the company’s commitment to advancing spinal care through innovative technologies.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

Hypnion is a neuroscience drug discovery and development company based in Worcester, Massachusetts, founded in 2000. The company specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness disorders, as well as circadian rhythm abnormalities. Hypnion utilizes its proprietary drug discovery platform, SCORE-2004, which measures the effects of drugs on sleep and wake parameters. This unique system enables the company to advance its research and development efforts effectively. In recognition of its innovative approach and contributions to the field, Hypnion was acquired by Eli Lilly and Company.

Innovative Spinal Technologies is a spine technology company based in Mansfield, Massachusetts, established in 2002. The company specializes in the development of motion preservation and minimally invasive treatments for spinal disorders. Its product portfolio includes the AXIENT Dynamic Fixation system, a pedicle screw-based motion system, and the PARAMOUNT Lumbar Fusion System, designed for lumbar fusion procedures in various surgical approaches, including minimally invasive and open techniques. Additionally, the PARAMOUNT MIS Pedicle Screw System caters to both single and multi-level procedures, while the PARAMOUNT Open Pedicle Screw System is tailored for minimally invasive lumbar fusion. The PARAMOUNT VBR is specifically engineered for a minimally invasive transforaminal approach, reflecting the company’s commitment to advancing spinal care through innovative technologies.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Hypnion is a neuroscience drug discovery and development company based in Worcester, Massachusetts, founded in 2000. The company specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness disorders, as well as circadian rhythm abnormalities. Hypnion utilizes its proprietary drug discovery platform, SCORE-2004, which measures the effects of drugs on sleep and wake parameters. This unique system enables the company to advance its research and development efforts effectively. In recognition of its innovative approach and contributions to the field, Hypnion was acquired by Eli Lilly and Company.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.